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GUEST EDITORIAL
Implications of an overview of chemotherapy in advanced ovarian
carcinoma
C.J. Williams
Department ofMedical Oncology, Royal South Hants Hospital, Brintons Terrace, OffSt. Mary's Road, Southampton S09 4PE, UK.
The history of clinical research into the management of
ovarian carcinoma is, in keeping with many other diseases,
littered with numerous small and inadequate trials. These
studies, often uncontrolled, were set up to show 'hoped for'
results and failed to take a hard look at what they might
reasonably have expected to achieve. This attitude has
bedevilled clinical research, often for understandable reasons,
but ways of overcoming the problem must be sought.
The results of the recent overview set up by the Medical
Research Council and conducted by the Advanced Ovarian
Trials Group (1991), at first look, make dismal reading - but
there are important conclusions to be drawn. The 5 year
survival figure for FIGO Stage III and IV disease of about
20% is reproducible in all of the trials in the overview and no
one treatment seems substantially better than another, despite
the introduction of the platinum group of drugs. Although
the overview addressed trials comparing single alkylating
agent therapy with cisplatin combinations, it is not possible
to say whether there is a survival advantage to platinum
based therapy. Survival benefit for the platinum combina-
tions was very small, not statistically significant, and was
only seen in the first 5 years. Interpretation of these results is
confounded by the use of cisplatin in many patients failing
alkylating agent therapy; these studies in effect addressing the
issue of immediate cisplatin based therapy vs deferred use of
such therapy. The overall poor results are the real world and
it should be remembered that these randomised trials only
included those patients deemed to be suitable for clinical
research - the results in a population-based study are bound
to be worse. However, closer examination of the data in the
overview (comparison 4) suggests that the addition of other
drugs to cisplatin may increase survival beyond 5 years by
5 10% (Cohen et al., 1983; GICOG (1987); Tomirotti et al.,
1988; Wiltshaw et al., 1986). This result is supported by a
recent overview of the role of doxorubicin which suggested
that its addition to cisplatin and cyclophosphamide also im-
proved survival (OCM-AP, 1991). If these results are true,
and despite the use of overviews there are still too few
patients to be sure, one question that arises is whether such
an improvement in survival is worthwhile. Is additional toxi-
city for all patients, especially hair loss caused by doxo-
rubicin, on top of that of platinum justified by improvement
in survival for a small group of patients. In other words,
should patients take a 90-95% chance that they could suffer
increased side effects without any survival benefit? In those
studies that have tackled similar questions, primarily in other
tumours, patients have by a large majority decided that such
small chances of improved survival are reason enough to
endure increased toxicity. (Coates & Simes, 1992). Viewed
from another angle even small improvements in long term
survival (in excess of 5 years) are important to individuals
and possibly also to the community since ovarian carcinoma
effects many tens of thousands of women world-wild each
year.
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Large scale randomised trials are needed now to establish
best current practice and so that future randomised trials of
new approaches have an optimal control group. For these
reasons the International Collaborative Ovarian Neoplasm
(ICON) group have developed trials for early and late
ovarian carcinoma (ICON 1 and 2). The overview of therapy
for advanced disease suggested that the addition of other
drugs to cisplatin improved long term survival but this result
needs to be tested prospectively in a large scale trial since
numbers in the overview were not particularly large and the
dose of cisplatin used in the single agent arm was generally
low (AOCTG, 1991). One explanation for the result could be
that improved survival was due to greater dose intensity
rather than use of additional agents.
The single agent chosen for this trial (ICON 2) is carbo-
platin, given in 'full' dosage with adjustment for GFR, since
the overview suggested equivalence with cisplatin (AOCTG,
1991) and it is much less toxic. The use of carboplatin will
give a maximal contrast with the cisplatin based combination
chosen (PAC - cisplatin, doxorubicin and cyclophosphamide
(Omura et al., 1989). PAC was chosen since a recent over-
view (Coates & Simes, 1991) has suggested that the addition
of doxorubicin to cyclophosphamide and cisplatin improves
survival significantly. ICON 2 aims to accrue in excess of
2,000 patients. If successful, it will clearly delineate 'best
current practice' (Whitehouse, 1989) which can be used as the
control for later studies.
As well as underlining a failure of investigaters to col-
laborate in clinical trials of adequate size the overview has
highlighted the inadequacy of present therapies. There is a
very real need for the development of active new treatments.
Previous phase II trials have been bedevilled by use of drugs
in patients who have failed extensive prior therapy and who
have very poor prognostic features. Although it can be
argued that really useful new drugs will be picked up in such
patients this view is difficult to test and there is a danger that
induction of multiple drug resistance by prior drug exposure
may result in failure to detect a very active compound. For
instance, doxorubicin has little or no activity in previously
treated patients (Hubbard et al., 1978) but appears to im-
prove survival when added to cisplatin and cyclophospha-
mide used as primary therapy. (OCM-AP, 1991). Although
lack of cross resistance is a highly desirable objective for a
new drug, it is not the only rational for testing new drugs -
current practice may, however, result in only this end being
served. In tumours such as ovarian cancer, where patients
with an extremely poor prognosis at presentation can be
identified, it may be possible to use phase II agents as
primary therapy without survival detriment. CA-125 levels
could be used to monitor response to the first or two cycles
of a phase II therapy in patients who had only had an initial
small biopsy (Rustin et al., 1991). A rise, or failure to fall, in
CA-125 could be regarded as evidence of disease progression
or failure to respond and would result in an immediate
change to standard therapy. This type of approach has had
limited use in poor risk testicular teratoma and needs to be
treated prospectively in other tumours (O'Reilly et al., 1992).
Randomisation to initial treatment with a phase II agent or
standard therapy with cross over on failure would allow
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assessment of any potential survival detriment caused by
primary use of a phase II agent.
The overview has shown that there are two striking needs
in the therapy of ovarian carcinoma: new more effective
drugs and development of best current therapy using drugs
presently available. A change in our attitude to the way we
run clinical trials will help us achieve these ends.
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